Cardiovascular disease in breast cancer patients: a nationwide real-world evidence study 2013–20
In this contemporary cohort, BC patients still had an increased risk of several CVDs compared to age-matched controls. Further research is needed to determine the causes of this increased risk, but clinicians should be aware and optimize therapy accordingly.
Authors
- Stephanie Brandal
- Ingrid Engebretsen (ORCID: https://orcid.org/0000-0001-9608-6731)
- Sigrun Halvorsen (ORCID: https://orcid.org/0000-0001-7561-7644)
- Christoffer Bugge (ORCID: https://orcid.org/0000-0002-0766-2870)
- Francisco Oteiza (ORCID: https://orcid.org/0000-0002-3747-9786)
- Elisabeth Floberghagen Birkelund
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- GlaxoSmithKline (United Kingdom) (GB)
- Pfizer (United Kingdom) (GB)
- Drammen Hospital (NO)
- GlaxoSmithKline (India) (IN)
Publication Details
- Journal
- European Heart Journal Open
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1093/ehjopen/oeaf043
- Citations
- 3
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Pfizer